MUSC Health’s Post

Ovarian cancer affects over 300,000 individuals every year and there is an urgent need for better treatment options to enhance remission rates and survival outcomes. Today, on World Ovarian Cancer Day, we are thrilled to present an encouraging study showcasing the effectiveness of a novel approach. Our TRC research chemicals played a crucial role in demonstrating the efficacy of a groundbreaking method that uses a nanotechnology system to deliver targeted oncology drug niraparib and chemotherapy doxorubicin in preclinical models of ovarian cancer. Learn more about the findings of this innovative study in Scientific Reports: https://okt.to/Zu4cG9 Toronto Research Chemicals #ProductCitation #WorldOvarianCancerDay #OvarianCancer #CancerReseacrch

I'm happy to share the latest achievement from my PhD student, Chung Shei Li. Her dedication and hard work have resulted in her second publication stemming from our research project. 📚 Titled "Optimization Studies of Mesoporous Silica Nanoparticles as a Drug Carrier for Gemcitabine: Enhancing Therapeutic Effectiveness in Pancreatic Cancer," her latest work is a significant step forward in our quest to develop a cutting-edge nanodelivery system. Our ultimate goal is to transform the treatment landscape of pancreatic cancer, often dubbed the "silent killer" due to its late-stage detection and bleak prognosis. We strive to achieve this by investigating a co-delivery of chemotherapy drugs and siRNA to elicit a synergistic effect, precisely targeting cancer cells. 💡 As materials engineers, our journey is anything but one-dimensional. It's a collaborative effort that transcends disciplinary boundaries, enriched by the contributions of valuable collaborators and driven by a passion for innovation and impact. Full paper available at https://lnkd.in/gk6vp6SX

We are delighted to announce that our review paper titled "Folate Receptor-Mediated Transporters in Cancer Therapy and Diagnosis“ is now online. Special thanks to the dedicated authors who contributed to the success of our paper. Your expertise and commitment have been invaluable. Kristian Wende Prof. Dr. Thomas von Woedtke #chemical #biology #nanomedicine #MyFirstChemSci #ChemSciVoices #drugdelivery #cancer #inp #ResearchTeam #rsc Chemical Science Journal

Since its inception by Doug Hanahan and Bob Weinberg in 2000, I am deeply intrigued by the “hallmarks of cancer” concept and its evolutionary steps in 2011 and 2022. Now, Prof. Hanahan (and colleagues) have published this “Cell Perspective” adding the “clouds of complexity” and mechanistic effectors “below the horizon”. I will stay curious to follow the concepts evolution in the future, that drew me into Molecular Biotechnology studies, cancer research and pharmaceutical sciences.

☕💻 📑 Let's kick off the week with a review article that looks at the challenges of omics technologies and provides an outlook on the future applications of these technologies in drug discovery and precision medicine for better management of cancer. In the review, the authors highlight the current trends in omics technologies and emphasise their role in understanding genotype-phenotype correlation in cancer in terms of 3D in vitro tumour models. https://lnkd.in/diHGtDra

Discover the future of drug discovery with PDX-derived organoid models (PDXOs)! These 3D in vitro models, derived from patient tumor tissues, faithfully mimic tumor complexity and offer unmatched predictive power for drug screening. Join us at the forefront of cancer research with PDXOs! Let's transform drug discovery and improve patient outcomes together. #CancerResearch #DrugDiscovery #PDXOrganoids #Innovation Crown Bioscience Crown Bioscience & MBL

Yey! Our paper was featured by UPD. Looking forward to the pre-clinical and clinical applications of these compounds. 🫶

The Evolution of Biobanking and its Role in Precision Oncology https://lnkd.in/eyf9hPJ6

Following the recent publication of Curve Therapeutics CSO Ali Tavassoli's research paper in the Journal of the American Chemical Society, Professor Tavassoli participated in a Q&A with Ellen Capon at Drug Target Review! The discussion delves into the science of HIF-inhibition, and its promise as a therapeutic approach for treating solid tumours. For the full article, see the link here: https://lnkd.in/eNtHBaiq #oncology #cancer #research #drugdiscovery

Thankful and fortunate to Dr. fatemeh mottaghitalab and other coauthors for their efficient guidance and constant support in this research article. Excited to have this publication and hope that it won't be my last. In this project, we conducted in vitro and in vivo studies to evaluate the efficacy of a special drug delivery system based on exosome nanostructure as a drug carrier and SP5-52 peptide as a targeting agent for the delivery of Doxorubicin to LL/2 lung cancer cell lines. If interested, check out this article on the Journal of drug delivery science and technology!